Skip to content

The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions

The Efficacy and Safety of the Dried Biological Amnion Graft Following Hysteroscopic Lysis for the Prevention of Postoperative Adhesions in Patients With Intrauterine Adhesions

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02496052
Enrollment
300
Registered
2015-07-14
Start date
2013-01-31
Completion date
2017-06-30
Last updated
2015-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrauterine Adhesions

Keywords

amnion graft, New biological barrier system

Brief summary

To estimate the efficacy and safety of dried biological amnion graft after hysteroscopic lysis of intrauterine adhesions.

Detailed description

Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention

Interventions

Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane

Device: Foley balloon Uterine application of Foley balloon

oral estradiol valerate tablets+dydrogesterone Tablets

Sponsors

Beijing Obstetrics and Gynecology Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* age 20-40 years; * previously diagnostic hysteroscopy confirmed adhesion score \>5, according to the American Fertility Society (AFS)classification of IUA; * complains of menstruation disorder and reproductive dysfunction; * informed consent.

Exclusion criteria

* premature menopause, * presence of other intrauterine lesions (e.g. polyps, myoma, septa), and * presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases), * adhesions limited to the lower uterine cavity or the cervical canal.

Design outcomes

Primary

MeasureTime frame
second diagnostic hysteroscopypostoperation three to four months

Countries

China

Contacts

Primary ContactWang Xin, MD
wx_0327@126.com13681401510
Backup ContactGan Lu, MD
gl19880508@163.com13552320665

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026